Previously reported target-adverse event associations in the context of secondary pharmacology profiling
Extract targets and associated adverse effects from three1-3 safety target panels and map them to the MedDRA vocabulary.
1 Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012;11(12):909‐922. doi: 10.1038/nrd3845 ↩
2 Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421‐1433. doi: 10.1016/S1359-6446(05)03632-9 ↩
3 Lynch JJ 3rd, Van Vleet TR, Mittelstadt SW, Blomme EAG. Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods. 2017;87:108‐126. doi: 10.1016/j.vascn.2017.02.020 ↩